title: Route-related variation in the immunogenicity of killed Salmonella enteritidis vaccine: role of antigen presenting cells.
abstract: In order to assess the role of the route of immunization on the immunogenicity of killed Salmonella vaccine, mice were immunized with killed S. enteritidis by intraperitoneal (i.p.) and intradermal (i.d.) routes. Whereas the former was non-immunogenic, the i.d. immunization generated an excellent delayed-type hypersensitivity response; further, i.p. immunization could even suppress the subsequent i.d. immunization. Since the peritoneal macrophages (MO) are known to be particularly low in Ia or MHC-class II antigens, so essential for antigen presentation, the non-immunogenicity by i.p. route was thought to be due to their poor presentation efficiency. Poly I: poly C, an interferon inducer, is known to enhance the MHC-class II expression; hence effect of poly I: poly C treatment on the immunogenicity of the killed vaccine by i.p. route was tested and indeed the non-immunogenicity was corrected. Poor efficiency of presentation of S. enteritidis antigen by peritoneal cells and its improvement by prior poly I: poly C treatment was further confirmed by in vitro lymphocyte transformation test using primed T cells and peritoneal cells from normal and poly I: poly C treated mice. Poly I: poly C treatment also enhanced expression of Ia antigens on peritoneal cells.
authors: Department of Immunology, Haffkine Institute, Parel, India.
authors: A
authors: A
authors: George
authors: K E
authors: KE
authors: Shroff
authors: S
authors: S
authors: Rath
authors: S N
authors: SN
authors: Ghosh
authors: S R
authors: SR
authors: Sengupta
authors: R S
authors: RS
authors: Kamat
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005557:Formaldehyde; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis / Q000276:immunology; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007372:Interferons / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010529:Peritoneal Cavity / Q000166:cytology; D011070:Poly I-C / Q000494:pharmacology; D011108:Polymers; D012477:Salmonella enteritidis / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D000949:Histocompatibility Antigens Class II; D011108:Polymers; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D005557:Formaldehyde; D007372:Interferons; D011070:Poly I-C; C003043:paraform